Fluorescent diagnosis of urinary bladder cancer—a comparison of two diagnostic modalities

Szygula, Michał; Wojciechowski, Boguslaw; Adamek, Mariusz; Pietrusa, Artur; Kawczyk‐Krupka, Aleksandra; Cebula, Wojciech; Zieleznik, Witold; Biniszkiewicz, Tomasz; Duda, Wiesław; Sieroń, Aleksander

doi:10.1016/s1572-1000(04)00006-7

Cited by 12 publications

(19 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 19 studies 51,53,[57][58][59][60][61][62][63]65,66,[70][71][72]77,78,80,81,84 involving 2327 participants, 946 (41%) presented with a suspicion of bladder cancer and 1381 (59%) had previously diagnosed bladder cancer. In two 72,78 of these studies the whole patient population (n = 102) had a suspicion of bladder cancer and in three 51,58,84 the whole population had previously diagnosed bladder cancer (n = 117). The remaining eight studies 50,52,54,56,67,73,76,85 did not report this information.…”

Section: Figurementioning

confidence: 99%

“…The remaining eight studies 50,52,54,56,67,73,76,85 did not report this information. In total, 18 50,53,54,56,58,59,[61][62][63]67,[70][71][72][73]77,78,84,85 (67%) of 27 studies used 5-ALA as the photosensitising agent, five 57,60,65,66,81 (19%) used HAL, two 52,76 (7%) used hypericin and two 51,80 used either 5-ALA or HAL but did report the number of patients receiving each agent.…”

Section: Figurementioning

confidence: 99%

“…Sixteen studies 50,51,53,56,[59][60][61][62][63]65,71,76,77,80,81,85 gave details of when they took place, with an earliest start date of February 1994 63 and latest end date of March 2006. 51 Nine studies took place in Germany, 54,56,58,61,70,71,80,84,85 Switzerland, 63 France, 72 Austria, 73 Poland, 78 South Korea 62 and China, 77 and four had multinational Germany/the Netherlands, 66 Germany/USA 67 and Switzerland/Norway/Sweden/Germany. 65 The four RCTs reporting recurrence/progression enrolled 709 participants, of whom 544 were included in the analysis.…”

Section: Figurementioning

confidence: 99%

“…The exception to this was the study by Koenig and colleagues,67 in which 55 patients were included but only 49 reported in the analysis. In 81% (22/27) of studies 50,[52][53][54]56,[58][59][60][61][62][63][65][66][67][70][71][72][73][76][77][78]84 a clear definition of what was considered to be a positive result was provided. In 96% (26/27) of studies it was unclear whether the same clinical data were available when the PDD test results were interpreted as would be available when the test was used in practice, the exception being the study by Ehsan and colleagues, 54 which stated that a detailed review of personal medical history was conducted for each patient before PDD.…”

Section: Figure 8 Summary Of Quality Assessment Of Rcts Reporting Recmentioning

confidence: 99%

“…In this context clinical data were defined broadly to include any information relating to the patient such as age, gender, presence and severity of symptoms, and other test results. In 59% (16/27) of studies 50,53,54,56,58,60,67,[70][71][72][73]77,78,81,84,85 it was unclear whether the reference standard results were interpreted without knowledge of the results of the PDD test. All of the studies were judged to suffer from incorporation bias in that PDD was not considered to be independent of the reference standard test as the biopsies used for the reference standard were obtained via the PDD procedure.…”

Section: Figure 8 Summary Of Quality Assessment Of Rcts Reporting Recmentioning

confidence: 99%

See 4 more Smart Citations

Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer

Campbell

Skea²,

Sutherland³

et al. 2010

Health Technol Assess

255

207

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address. Paying by credit cardYou can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume. How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. NIHR Health Technology Assessment programmeT he Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. F...

show abstract

Section: Figurementioning

confidence: 99%

Section: Figurementioning

confidence: 99%

Section: Figurementioning

confidence: 99%

Section: Figure 8 Summary Of Quality Assessment Of Rcts Reporting Recmentioning

confidence: 99%

Section: Figure 8 Summary Of Quality Assessment Of Rcts Reporting Recmentioning

confidence: 99%

See 3 more Smart Citations

Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer

Campbell

Skea²,

Sutherland³

et al. 2010

Health Technol Assess

255

207

View full text Add to dashboard Cite

show abstract

Bladder Cancer Screening—Systematic Review Results

Goonewardene

Persad

Motiwala

et al. 2019

Management of Non-Muscle Invasive Bladder Cancer

View full text Add to dashboard Cite

Novel real-time optical imaging modalities for the detection of neoplastic lesions in urology: a systematic review

2018

View full text Add to dashboard Cite

Background Current optical diagnostic techniques for malignancies are limited in their diagnostic accuracy and lack the ability to further characterise disease, leading to the rapidly increasing development of novel imaging methods within urology. This systematic review critically appraises the literature for novel imagining modalities, in the detection and staging of urological cancer and assesses their effectiveness via their utility and accuracy. Methods A systematic literature search utilising MEDLINE, EMBASE and Cochrane Library Database was conducted from 1970 to September 2018 by two independent reviewers. Studies were included if they assessed real-time imaging modalities not already approved in guidelines, in vivo and in humans. Outcome measures included diagnostic accuracy and utility parameters, including feasibility and cost. Results Of 5475 articles identified from screening, a final 46 were included. Imaging modalities for bladder cancer included optical coherence tomography (OCT), confocal laser endomicroscopy, autofluorescence and spectroscopic techniques. OCT was the most widely investigated, with 12 studies demonstrating improvements in overall diagnostic accuracy (sensitivity 74.5–100% and specificity 60–98.5%). Upper urinary tract malignancy diagnosis was assessed using photodynamic diagnosis (PDD), narrow band imaging, optical coherence tomography and confocal laser endomicroscopy. Only PDD demonstrated consistent improvements in overall diagnostic accuracy in five trials (sensitivity 94–96% and specificity 96.6–100%). Limited evidence for optical coherence tomography in percutaneous renal biopsy was identified, with anecdotal evidence for any modality in penile cancer. Conclusions Evidence supporting the efficacy for identified novel imaging modalities remains limited at present. However, OCT for bladder cancer and PDD in upper tract malignancy demonstrate the best potential for improvement in overall diagnostic accuracy. OCT may additionally aid intraoperative decision making via real-time staging of disease. Both modalities require ongoing investigation through larger, well-conducted clinical trials to assess their diagnostic accuracy, use as an intraoperative staging aid and how to best utilise them within clinical practice.

show abstract

Fluorescent diagnosis of urinary bladder cancer—a comparison of two diagnostic modalities

Cited by 12 publications

References 7 publications

Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer

Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer

Bladder Cancer Screening—Systematic Review Results

Novel real-time optical imaging modalities for the detection of neoplastic lesions in urology: a systematic review

Contact Info

Product

Resources

About